[AEONCR] QoQ TTM Result on 31-May-2024 [#1]

Stock
[AEONCR] AEON CREDIT SERVICE (M) BHD
Announcement Date
10-Jul-2024
Admission Sponsor
-
Sponsor
-
Financial Year
28-Feb-2025
Quarter
31-May-2024 [#1]
Profit Trend
QoQ- 1.66%
YoY- 21.78%
Quarter Report
Latest QR
Upcoming QR
AEONCR's Result
AEONCR's Financial Summary
View:
Show?
TTM Result
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
Revenue 2,127,257 2,051,775 1,982,076 1,912,491 1,843,581 1,774,907 1,702,348 15.96%
PBT 496,406 519,990 578,085 565,174 532,390 522,539 463,355 4.68%
Tax -137,842 -137,953 -147,017 -141,156 -131,952 -124,020 -109,376 16.62%
NP 358,564 382,037 431,068 424,018 400,438 398,519 353,979 0.85%
-
NP to SH 358,564 382,037 431,068 424,018 400,438 398,519 353,979 0.85%
-
Tax Rate 27.77% 26.53% 25.43% 24.98% 24.78% 23.73% 23.61% -
Total Cost 1,768,693 1,669,738 1,551,008 1,488,473 1,443,143 1,376,388 1,348,369 19.76%
-
Net Worth 2,710,589 2,725,851 2,731,792 2,639,881 2,512,227 2,502,015 2,430,529 7.51%
Dividend
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
Div 144,226 144,226 144,248 144,248 126,377 126,377 126,377 9.18%
Div Payout % 40.22% 37.75% 33.46% 34.02% 31.56% 31.71% 35.70% -
Equity
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
Net Worth 2,710,589 2,725,851 2,731,792 2,639,881 2,512,227 2,502,015 2,430,529 7.51%
NOSH 510,468 510,459 510,615 510,615 510,615 255,307 255,307 58.50%
Ratio Analysis
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
NP Margin 16.86% 18.62% 21.75% 22.17% 21.72% 22.45% 20.79% -
ROE 13.23% 14.02% 15.78% 16.06% 15.94% 15.93% 14.56% -
Per Share
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
RPS 416.73 401.95 388.17 374.55 361.05 695.20 666.78 -26.83%
EPS 70.24 74.84 84.42 83.04 78.42 156.09 138.65 -36.37%
DPS 28.25 28.25 28.25 28.25 24.75 49.50 49.50 -31.12%
NAPS 5.31 5.34 5.35 5.17 4.92 9.80 9.52 -32.16%
Adjusted Per Share Value based on latest NOSH - 510,615
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
RPS 416.73 401.94 388.29 374.65 361.15 347.70 333.49 15.96%
EPS 70.24 74.84 84.45 83.06 78.45 78.07 69.34 0.86%
DPS 28.25 28.25 28.26 28.26 24.76 24.76 24.76 9.16%
NAPS 5.31 5.3399 5.3515 5.1715 4.9214 4.9014 4.7614 7.51%
Price Multiplier on Financial Quarter End Date
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
Date 29/11/24 30/08/24 31/05/24 29/02/24 30/11/23 30/08/23 31/05/23 -
Price 6.76 7.10 7.24 6.34 5.70 11.00 11.40 -
P/RPS 1.62 1.77 1.87 1.69 1.58 1.58 1.71 -3.53%
P/EPS 9.62 9.49 8.58 7.63 7.27 7.05 8.22 11.02%
EY 10.39 10.54 11.66 13.10 13.76 14.19 12.16 -9.93%
DY 4.18 3.98 3.90 4.46 4.34 4.50 4.34 -2.46%
P/NAPS 1.27 1.33 1.35 1.23 1.16 1.12 1.20 3.84%
Price Multiplier on Announcement Date
30/11/24 31/08/24 31/05/24 29/02/24 30/11/23 31/08/23 31/05/23 CAGR
Date 19/12/24 26/09/24 10/07/24 08/04/24 21/12/23 26/09/23 10/07/23 -
Price 6.10 7.35 7.24 6.61 5.63 11.44 11.18 -
P/RPS 1.46 1.83 1.87 1.76 1.56 1.65 1.68 -8.90%
P/EPS 8.68 9.82 8.58 7.96 7.18 7.33 8.06 5.05%
EY 11.52 10.18 11.66 12.56 13.93 13.64 12.40 -4.77%
DY 4.63 3.84 3.90 4.27 4.40 4.33 4.43 2.97%
P/NAPS 1.15 1.38 1.35 1.28 1.14 1.17 1.17 -1.13%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment